$Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa$

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa

Introduction Andexanet alfa (andexanet) is an approved antidote used to reverse the bleeding effects of Direct Oral Anticoagulant (Direct-Xa agents) agents because it reverses anti-Xa activity. Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) exhibit anti-Xa activity. The purpo...

Full description

Bibliographic Details
Main Authors:	Joseph Lewis BA, Omer Iqbal MD, Walter Jeske PhD, Debra Hoppensteadt PhD, Fakiha Siddiqui BDS, Jawed Fareed PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-05-01
Series:	Clinical and Applied Thrombosis/Hemostasis
Online Access:	https://doi.org/10.1177/10760296221099934

Similar Items

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-01-01)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
by: Siddharth Mehrotra, et al.
Published: (2022-12-01)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-12-01)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
by: Fakiha Siddiqui BDS, et al.
Published: (2020-10-01)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
by: Jianle Chen BS, et al.
Published: (2019-04-01)

Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin
by: Guy Olson BS, et al.
Published: (2023-03-01)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
by: Fakiha Siddiqui BDS, et al.
Published: (2019-05-01)

Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version
by: Dalia Qneibi MD, et al.
Published: (2020-09-01)

Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins
by: Ahmed Kouta MS, MBA, et al.
Published: (2019-11-01)

Successful use of an antithrombin for heparin resistance with andexanet alfa
by: Jun Honda, et al.
Published: (2023-05-01)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
by: C. James Watson, et al.
Published: (2019-11-01)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
by: Thompson David, et al.
Published: (2006-09-01)

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
by: Jawed Fareed PhD, et al.
Published: (2019-09-01)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
by: Alpesh Amin, et al.
Published: (2023-06-01)

The refractory effective of unfractionated heparin during an open aneurysm repair post-andexanet administration: A case report
by: Laura T. Boitano, et al.
Published: (2022-06-01)

Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight
by: David Michael Kaylor PharmD, et al.
Published: (2023-02-01)

Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels
by: Walter Jeske, et al.
Published: (2019-01-01)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
by: Milne Ruairidh, et al.
Published: (2001-10-01)

Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?
by: Nil Guler MD, et al.
Published: (2020-07-01)

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
by: Colin Pawlowski, et al.
Published: (2021-03-01)

Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates
by: Ahmed Kouta MS, MBA, et al.
Published: (2020-10-01)

The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients
by: Bulent Kantarcioglu MD, et al.
Published: (2022-04-01)

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients
by: Madeline Allen BS, et al.
Published: (2023-04-01)

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
by: Jeske W, et al.
Published: (2013-06-01)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
by: Alex C. Spyropoulos MD, et al.
Published: (2022-07-01)

Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy
by: Oleksandr Oliynyk, et al.
Published: (2021-09-01)

PHARMACO-ECONOMIC COMPARISON OF ENOXAPARIN AND UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION
by: A. V. Syrov, et al.
Published: (2010-04-01)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
by: Pineo GF, et al.
Published: (2012-04-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
by: Hosein Vakili, et al.
Published: (2007-04-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
by: Hosein Vakili, et al.
Published: (2007-07-01)

Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates
by: Ahmed Kouta MS, MBA, et al.
Published: (2021-04-01)

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism
by: Alexander O’Hara BS, et al.
Published: (2023-03-01)

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism
by: Bulent Kantarcioglu MD, et al.
Published: (2022-06-01)

Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy
by: Amanda Walborn PhD, et al.
Published: (2020-03-01)

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey
by: Charles Fasanya MD, FRCS FACS, et al.
Published: (2024-03-01)

The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?
by: Pieter M.M. De Kesel, et al.
Published: (2020-01-01)

Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure
by: Alpesh N. Amin, et al.
Published: (2024-02-01)

Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery
by: Luminita Iliuta, et al.
Published: (2022-08-01)

Andexanet alfa - what we know about this promising drug
by: Natalia Ilnicka, et al.
Published: (2023-09-01)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
by: Elise Carpenter, et al.
Published: (2019-11-01)